BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 35277453)

  • 1. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes.
    Ting NL; Lau HC; Yu J
    Gut; 2022 Jul; 71(7):1412-1425. PubMed ID: 35277453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out.
    Conti G; D'Amico F; Fabbrini M; Brigidi P; Barone M; Turroni S
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex interactions between the microbiome and cancer immune therapy.
    Schwartz DJ; Rebeck ON; Dantas G
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota modulation: a tool for the management of colorectal cancer.
    Wang Y; Li H
    J Transl Med; 2022 Apr; 20(1):178. PubMed ID: 35449107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
    Lu Y; Yuan X; Wang M; He Z; Li H; Wang J; Li Q
    J Hematol Oncol; 2022 Apr; 15(1):47. PubMed ID: 35488243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota: a potential target for improved cancer therapy.
    Zhao M; Jiang G; Zhou H; Li J; Xiang W; Li S; Wang H; Zhou J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):541-552. PubMed ID: 36550389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
    Lau HCH; Sung JJ; Yu J
    Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics.
    Kaźmierczak-Siedlecka K; Daca A; Fic M; van de Wetering T; Folwarski M; Makarewicz W
    Gut Microbes; 2020 Nov; 11(6):1518-1530. PubMed ID: 32453670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
    Haak BW; Prescott HC; Wiersinga WJ
    Front Immunol; 2018; 9():2042. PubMed ID: 30250472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
    Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
    Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota Manipulation as a Tool for Colorectal Cancer Management: Recent Advances in Its Use for Therapeutic Purposes.
    Perillo F; Amoroso C; Strati F; Giuffrè MR; Díaz-Basabe A; Lattanzi G; Facciotti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiome in modulating immune checkpoint inhibitors.
    Li X; Zhang S; Guo G; Han J; Yu J
    EBioMedicine; 2022 Aug; 82():104163. PubMed ID: 35841869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The triple interactions between gut microbiota, mycobiota and host immunity.
    Yang J; Yang H; Li Y
    Crit Rev Food Sci Nutr; 2023 Nov; 63(33):11604-11624. PubMed ID: 35776086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiome bacterial influencers of host immunity and response to immunotherapy.
    Yousefi Y; Baines KJ; Maleki Vareki S
    Cell Rep Med; 2024 Apr; 5(4):101487. PubMed ID: 38547865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the complex and multifaceted interplay of the gut microbiome and cancer prevention and therapy.
    Kashyap S; Das A
    Acta Microbiol Immunol Hung; 2023 Jun; 70(2):85-99. PubMed ID: 37307215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota in Cancer Immune Response and Immunotherapy.
    Zhou CB; Zhou YL; Fang JY
    Trends Cancer; 2021 Jul; 7(7):647-660. PubMed ID: 33674230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.